Summit, New Jersey-based Kenvue Inc. (KVUE) operates as a consumer health company in the United States and internationally. The company has a market cap of $34.4 billion and operates through Self Care, Skin Health and Beauty, and Essential Health segments.
Companies with a market cap of $10 billion or more are typically referred to as “big-cap stocks.” KVUE fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the household and personal products industry.
More News from Barchart
Despite its strength, KVUE stock slipped 21.6% from its 52-week high of $22.87, reached on July, 25, 2025. The stock is down 1.3% over the past three months, underperforming the S&P 500 Index’s ($SPX) 8.7% rise during the same time frame.
Moreover, KVUE has lagged behind the broader market over the longer term. The stock has declined 15.9% over the past 52 weeks, while SPX delivered 23% returns over the same time frame.
KVUE has been trading above its 200-day and 50-day moving averages since last week.
On May 7, KVUE stock rose marginally following the release of its Q1 2026 earnings. The company’s revenue for the quarter amounted to $3.9 billion, surpassing the Street’s estimates. Moreover, its adjusted EPS came in at $0.32, also topping Wall Street’s forecasts.
When stacked against its peer, Kimberly-Clark Corporation (KMB), KVUE has outperformed. Over the past year, KMB stock has declined 24.2%.
Wall Street has a skeptical view of the stock currently. Among the 13 analysts tracking KVUE, the overall consensus stands at a “Hold.” Its mean price target of $19 suggests 6% upside potential from current price levels.
On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com